VIRS Profile
The
Pacer BioThreat Strategy ETF is an exchange-traded fund that seeks to
provide investors with exposure to companies that are involved in the
development and manufacturing of products and services designed to
protect against biological threats. The fund is managed by Pacer ETFs,
an investment management company that specializes in thematic ETFs.
As of September 2021, the VIRS ETF had a net asset value of
approximately $12 million and held 35 individual stocks. The fund's
portfolio is comprised of companies involved in various aspects of
biosecurity, such as the development of vaccines, diagnostics, and
therapeutics for infectious diseases, as well as companies involved in
the manufacturing of personal protective equipment (PPE) and other
biosecurity-related products.
The COVID-19 pandemic has
highlighted the importance of preparedness for biological threats, and
the VIRS ETF is designed to provide investors with exposure to
companies that are positioned to benefit from increased demand for
biosecurity-related products and services.
The expense ratio
for the VIRS ETF is 0.70%, which is relatively high compared to some
other ETFs. However, the VIRS ETF is a niche product that offers
exposure to a specific segment of the healthcare and technology
industries.
Overall, the Pacer BioThreat Strategy ETF may be a
suitable investment for investors seeking exposure to companies
involved in the development and manufacturing of products and services
designed to protect against biological threats. However, as with any
investment, it is important to consider the unique risks and
challenges of the healthcare and technology industries, as well as the
relatively high expense ratio of the fund. Investors should also
conduct their own research and consider their investment goals and
risk tolerance before investing i
|
